Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13108101 | 0.88 | ACACB (0.51) | LDHAACACBPPARGPPARA | |
| SCHEMBL8628683 | 0.84 | ESR1 (0.47) | ITGA4ITGB7 | |
| SCHEMBL15697338 | 0.84 | ESR1 (0.47) | ITGA4ITGB7 | |
| SCHEMBL13623718 | 0.83 | LDHA (0.61) | LDHASLC6A4ACACBALDH1A1HTT | |
| SCHEMBL7518497 | 0.83 | LDHA (0.53) | LDHASLC6A4MMP1ACACBPPARG | |
| SCHEMBL7346010 | 0.83 | LDHA (0.53) | LDHASLC6A4MMP1ACACBPPARG | |
| SCHEMBL106531 | 0.83 | LDHA (0.53) | LDHASLC6A4MMP1ACACBPPARG | |
| SCHEMBL13575226 | 0.83 | LDHA (0.53) | LDHASLC6A4MMP1ACACBPPARG | |
| SCHEMBL12317087 | 0.83 | CYP3A4 (0.42) | CYP1A2CYP2D6CYP2C19ITGA4ITGB7 | |
| SCHEMBL17022258 | 0.82 | LMNA (0.51) | ACACBALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| EP-2632269-B1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9221834-B2 | Cyclic amine substituted oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130331372-A1 | Cyclic Amine Substituted Oxazolidinone CETP Inhibitor | MERCK SHARP & DOHME CORP. | 2013-12-12 | — | — | US | disclosed |
| EP-2632269-A1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058187-A1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331372-A1 | Cyclic Amine Substituted Oxazolidinone CETP Inhibitor | CETP, APOB, MTTP | LDHA 3831/4885SLC6A4 4038/4885MMP1 3133/4885 |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | F7, F11, HABP2 | LDHA 2069/4885SLC6A4 1640/4885MMP1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.